GlassScriptPhysician profile
John Charles Hammond
NPI 1154766905
$4,772.82
in general payments reported to CMS, 2019-2025
25 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.15 · 2020: $271 · 2021: $720 · 2022: $843 · 2023: $748 · 2024: $920 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,844.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $633.81 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $600.09 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $462.06 | 2020-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $415.51 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $366.74 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $313.14 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $298.68 | 2019-2023 | Aplenzin |
| Neurocrine Biosciences, INC. | $278.23 | 2020-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.74 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $183.99 | 2021-2023 | Belsomra |
| Teva Pharmaceuticals USA, INC. | $183.09 | 2022-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $156.64 | 2024-2025 | Dyanavel Xr |
| Alkermes, INC. | $149.52 | 2023-2025 | Aristada, Lybalvi |
| Alpha Cognition USA, INC. | $92.32 | 2025 | Zunveyl |
| Acadia Pharmaceuticals INC | $92.22 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $84.54 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $51.53 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $47.12 | 2019-2021 | |
| Almatica Pharma LLC | $40.80 | 2022 | |
| Spinal Simplicity, LLC | $30.62 | 2025 | Ha Minuteman G3-R |
| Supernus Pharmaceuticals, INC. | $22.96 | 2023 | Qelbree |
| Noven Therapeutics, LLC | $19.71 | 2024 | Secuado, Xelstrym |
| Collegium Pharmaceutical, INC. | $19.07 | 2024 | Xtampza |
| Eisai INC. | $19.06 | 2021 | |
| Neos Therapeutics, LP | $14.63 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.